MARKET

ALNY

ALNY

Alnylam Pharmaceuticals Inc
NASDAQ
292.16
+5.89
+2.06%
Opening 15:10 05/19 EDT
OPEN
284.38
PREV CLOSE
286.27
HIGH
294.93
LOW
284.38
VOLUME
376.72K
TURNOVER
--
52 WEEK HIGH
495.55
52 WEEK LOW
284.19
MARKET CAP
39.01B
P/E (TTM)
69.59
1D
5D
1M
3M
1Y
5Y
1D
IBB, GILD, REGN, ALNY: ETF Outflow Alert
NASDAQ · 8h ago
Alnylam Pharmaceuticals Initiated at Buy by Citigroup
Dow Jones · 8h ago
Alnylam Pharmaceuticals Price Target Announced at $380.00/Share by Citigroup
Dow Jones · 8h ago
Citigroup Initiates Coverage On Alnylam Pharmaceuticals with Buy Rating, Announces Price Target of $380
Benzinga · 8h ago
StubHub, Jazz Pharmaceuticals upgraded: Wall Street’s top analyst calls
TipRanks · 9h ago
Alnylam publishes 2025 corporate responsibility report
PUBT · 10h ago
How HELIOS-B Phase 3 Vutrisiran Data and Real-World Evidence Expansion Will Impact Alnylam (ALNY) Investors
Simply Wall St · 12h ago
ALNYLAM PHARMACEUTICALS INC <ALNY.O>: CITIGROUP INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $380
Reuters · 12h ago
More
About ALNY
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults ; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Zilebesiran, Elebsiran, Mivelsiran, ALN-6400, and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.

Webull offers Alnylam Pharmaceuticals, Inc. stock information, including NASDAQ: ALNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALNY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALNY stock methods without spending real money on the virtual paper trading platform.